Network and Data - CENTOGENE has built a network of approximately 30,000 active physicians since its founding in 2006[5] - The CENTOGENE Biodatabank includes data from over 750,000 patients across more than 120 countries, with over 70% being of non-European descent[5] - CENTOGENE's multiomic reference laboratories are ISO, CAP, and CLIA certified, utilizing various datasets for diagnosis[5] Collaborations and Research - The company has supported over 50 collaborations with pharmaceutical partners to accelerate drug discovery and commercialization[6] - CENTOGENE has contributed to generating novel insights for more than 275 peer-reviewed publications[5] Financial and Growth Strategy - Shareholders approved the external audit by Ernst & Young for the financial years ended December 31, 2022, and December 31, 2023[3] - The company aims to achieve sustainable growth and profitability through data-driven solutions for rare and neurodegenerative diseases[4] - The company is focused on expanding its market presence and enhancing its product pipeline[6] - The management board has been authorized to issue shares and limit pre-emption rights, indicating potential for future capital raising[3] Risks and Forward-Looking Statements - Forward-looking statements highlight risks including economic conditions, regulatory approvals, and reliance on third parties[8]
Centogene(CNTG) - 2023 Q2 - Quarterly Report